However, due to intrinsic or acquired resistance against ET, about 40% of patients relapse after ET and approximately 50% of patients with locally advanced or metastatic ERα-positive BC do not respond to first-line endocrine treatment [7,8]. This evidence concerns the gene ESR1 and breast cancer.